Sherif S. Attalla
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.
Journal: JCI insight
Published: August 20, 2025
HER2∆16 directs luminal cell identity and estrogen receptor signaling in HER2+ breast cancer.
Journal: Nature communications
Published: June 03, 2025
Osteopontin is a therapeutic target that drives breast cancer recurrence.
Journal: Nature communications
Published: April 05, 2024
Targeting fatty acid oxidation enhances response to HER2-targeted therapy.
Journal: Nature communications
Published: January 10, 2024
The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.
Journal: Immunity
Published: March 23, 2023
Tailoring therapies to counter the divergent immune landscapes of breast cancer.
Journal: Frontiers in cell and developmental biology
Published: November 30, 2022
Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
Journal: The Journal of clinical investigation
Published: June 22, 2022
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer.
Journal: Cancer immunology research
Published: February 24, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026